This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OPHT IVERIC bio (OPHT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About IVERIC bio Stock (NASDAQ:OPHT) 30 days 90 days 365 days Advanced Chart Get IVERIC bio alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.13▼$1.3952-Week Range N/AVolumeN/AAverage Volume159,109 shsMarket Capitalization$1.65 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY. Read More Receive OPHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address OPHT Stock News HeadlinesGossamer Bio Inc GOSSNovember 5, 2023 | morningstar.comMIveric Bio ticks higher as it sees sale to Astellas closing July 11June 29, 2023 | msn.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them. | American Alternative (Ad)Iveric Bio falls amid concern about Astellas dealJune 29, 2023 | msn.comBaird Downgrades IVERIC bio (ISEE)May 6, 2023 | msn.comApellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric BioMay 6, 2023 | msn.comIveric Bio (NASDAQ:ISEE) Sold for $5.9BMay 1, 2023 | msn.comAstellas to Buy Eye-Drug Maker Iveric Bio for $5.9 BillionMay 1, 2023 | msn.comSee More Headlines OPHT Stock Analysis - Frequently Asked Questions How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:OPHT) issued its quarterly earnings results on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.02. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), Meta Platforms (META) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings10/31/2018Today7/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OPHT CIK1410939 Webwww.ophthotech.com Phone(212) 845-8200FaxN/AEmployees35Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$63.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-141.53% Return on Assets-41.88% Debt Debt-to-Equity RatioN/A Current Ratio10.09 Quick Ratio10.09 Sales & Book Value Annual Sales$209.98 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / BookN/AMiscellaneous Outstanding Shares41,420,000Free FloatN/AMarket Cap$1.65 billion OptionableOptionable Beta1.49 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:OPHT) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IVERIC bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
